VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds


Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Go
Feedback
You are here : IndiaNotes >> Research & Analysis >> Companies >> Neuland Laboratories Ltd. >> Research

Neuland Laboratories: Buy with medium to long term perspective for ~25% appreciation

Hem Securities | 26 Aug, 2016  | Follow Author | Add to my Favourites 
  • Rate this article
    (Average Rating 0.0 Based on 0 ratings)



Valuation


With change in business mix, focus on high margin value added segment, robust number of filings, preferred pure API player and wide geographical presence bodes well for growth of Neuland Laboratories Ltd. We believe the company is trading at an attractive valuation at 25.40x and 20.18x of consolidated FY17EPS of Rs.40.31 and FY18EPS of Rs.50.76. We initiate a ‘BUY’ on the stock with a target price of Rs.1280 (appreciation of about 25%) with the medium to long term investment horizon.


  • Neuland Laboratories Limited, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries.
  • The company has registered decent results for the quarter ending June 2016. The standalone revenues grew by 21% to Rs.149.77 crores vs. Rs.123.72 cr. in the year ago quarter. Operating profit grew at Rs.24.56 crores as against Rs.21.11 crores in the corresponding quarter last year; representing growth of 16.8%. The adjusted net profit surged sharply at Rs.9.71 crore as against Rs.7.30 crore, depicting a sharp growth of 33% y-o-y.
  • This quarter has been the best quarter for the company in terms of revenues coupled with sustained EBIDTA margins and profitability. The strong performance is a result of various transformational initiatives taken by the company over last few quarters.
  • The total operating revenues for the Q1FY17 account for 47% (66% for Q1FY16 and 51% for Q4FY16) from prime products, 29% (30% for Q1FY16 and 25% for Q4FY16) from niche APIs and the remaining 23% (4% for Q1FY16 and 23% from Q4FY16) from CMS business.
  • The Company is working on 10 projects (9 in Q4FY16 and 1 in Q1FY16) of which 6 are in commercial stage and remaining 4 being in the clinical stage.

 


  Read full report Click here to read the full report

logo
BSE
1,269.00 -30.00
(-2.31%)
NSE
1,275.85 -22.00
(-1.70%)
Read More
About Hem Securities
The Hem Securities is one of the leading broking Network in India. It provides trading platform in all the leading exchanges namely - BSE, NSE, MCX , NCDEX & MCX-SX. Their mission is to build wealth for their investors by offering them best financial services through trading & investment strategies and honoring commitment with ethical & transparent business practices.

For more information please write in to [email protected]
Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor IndiaNotes.com accept any liability whatsoever arising from the use of any of the above contents.



Technical Calls

What are technical calls?

Other Articles


Have a question?